your initial deposit *subject to change and depends on individual circumstances.
ImmunoCellular Therapeutics, Ltd. is a development-stage company. The Company is seeking to develop and commercialize new therapeutics to fight cancer using the immune system. The product candidate portfolio includes cellular immunotherapies targeting cancer and cancer stem cell antigens, peptide based immunotherapies...Read more
ImmunoCellular Therapeutics CEO to speak at Phacilitate Immunotherapy Leaders' ForumMay 08 2012, 6:23pm
Dr. Singh will speak at the forum taking place from May 9-11, and will deliver the Chair’s introductory presentation titled: "A retrospective of the past 15 years of novel immunotherapy products— from Rituxan™ to Adcetris™," to begin at 9:00 am local time on Wednesday May 9th.
The Phacilitate Immunotherapy Leaders' Forum is an annual gathering place for senior executives and scientists driving the development of immunotherapies. The event is focused on overcoming the challenges involved in bringing these technologies to the market.
ImmunoCellular is a clinical-stage biotech company based in Los Angeles. The company focuses on the development of new immune-based products in the treatment and diagnosis of brain and other cancers.
A phase II trial recently started on the company's leading product candidate, ICT-107, a dendritic cell-based vaccine that targets multiple tumour-associated antigens for glioblastoma, an aggressive form of brain cancer.
This is done by removing dendritic cells from a patient, loading them with the tumour-related antigens, and re-injecting them back into the patient's body to trigger an immune response against cancer cells exhibiting these antigens.
Rather than simply targeting a single tumour-specific antigen, IMUC’s vaccine tracks multiple different antigens found on cancer stem cells.
Cancer stem cells are thought to be the originators of common tumour cells, and lead to cancer’s re-growth after chemotherapy. It is believed that destroying the cancer stem cells will allow for longer survival, without relapse.
Details of the conference may be found at http://www.phacilitate.co.uk/event.php?eid=12&pid=282